Table 1. Summary of patient demographics of the Nottingham primary BC series used in this study.

Parameter	Number (%)
Age
⩽50 years	367 (38.3)
>50 years	591 (61.6)
Median/mean	54
Menopausal status
Premenopausal	381 (39.7)
Postmenopausal	577 (60.2)
Tumour grade
1	129 (13.6)
2	300 (31.6)
3	521 (54.8)
Pleomorphisms
1	13 (1.4)
2	314 (33.9)
3	599 (64.7)
Tubule formation
1	45 (4.8)
2	308 (33.3)
3	574 (61.9)
Mitotic figures
1	267 (28.8)
2	196 (21.2)
3	463 (50.0)
Tumour size
⩽2 cm	543 (56.6)
>2 cm	404 (42.1)
Axillary nodal stage
1 (Node negative)	571 (59.5)
2 (1–3 positive nodes)	304 (31.7)
3 (⩾4 positive nodes)	78 (8.1)
Nottingham Prognostic Index (NPI)
Good NPI (<3.4)	247 (26.0)
Moderate NPI (3.41–5.4)	530 (55.7)
Poor NPI (⩾5.4)	174 (18.3)
Histological tumour type
Ductal no special type (NST)	578 (62.3)
Tubular mixed	158 (17.0)
Medullary (typical and atypical)	23 (2.5)
Lobular*	73 (7.9)
Excellent Prognosis Special Groups**	38 (4.1)
Mixed NST and lobular	39 (4.2)
Mixed NST and other special type	19 (2.0)
LVI Negative	612 (65.2)
Definite	327 (34.8)
Distant metastasis
Negative	567 (60.1)
Positive	376 (39.2)
Survival (month)
Overall survival: Median/mean (range)	168/149.6 (1–308)
DFI: Median/mean (range)	109/100 (2–239)
ER status
ER positive	271 (28.5)
ER negative	681 (71.5)
PR status
PR positive	407 (43.8)
PR negative	522 (56.2)
HER2 status
HER2 positive	786 (85.4)
HER2 negative	131 (13.2)
Molecular subtype
Luminal	614 (65.9)
HER2 positive	131 (14.1)
Triple negative	187 (20.0)

Abbreviations: ER=oestrogen receptor; HER2=human epidermal growth factor receptor 2; LVI=lymphovascular invasion; PR=progesterone receptors.

^*Invasive lobular includes: classic lobular, tubulo-lobular, alveolar lobular, solid lobular, pleomorphic lobular, and lobular mixed carcinomas.

^**Excellent prognostic special types comprise: mucinous carcinoma, cribriform carcinoma, tubular carcinoma and invasive papillary carcinoma.